How to Preserve Muscle While Taking GLP-1 Weight-Loss

Why Can Muscle Decline During GLP-1 Weight Loss?

Loss of lean mass is not unique to medicines such as semaglutide or tirzepatide; it can occur during weight loss produced by diet, surgery or medication. GLP-1–based drugs reduce appetite, and some also slow gastric emptying, making it easier to consume fewer calories. If the resulting energy deficit is large and resistance exercise or protein intake is inadequate, the body may draw on lean tissue alongside stored fat.

Body-composition substudies of major weight-loss trials indicate that most weight reduction comes from fat, although lean mass also decreases. Lean mass measured by dual-energy X-ray absorptiometry is not identical to skeletal muscle because it also includes organs, connective tissue and body water. Clinicians should therefore consider strength, mobility and physical function rather than interpreting a scan result alone.

How Can Patients Preserve Muscle While Taking a GLP-1 Drug?

U.S. physical activity guidelines recommend muscle-strengthening activity involving all major muscle groups on at least two days each week. Patients can use weights, resistance bands, machines or body-weight exercises, beginning at an appropriate level and gradually increasing the challenge. Older adults, people with limited mobility and those with heart, joint or neurological conditions may benefit from guidance from a physical therapist or qualified exercise professional.

Protein should be included regularly through foods such as fish, eggs, dairy products, beans, lentils, soy foods, poultry or lean meat. The adult Recommended Dietary Allowance is 0.8 grams per kilogram of body weight per day, but individual needs during weight loss can differ according to age, activity, illness and kidney function. A clinician or registered dietitian can help set a safe target, particularly when nausea, early fullness or other adverse effects make adequate eating difficult.

When Should Muscle and Nutrition Be Clinically Reviewed?

Monitoring can include weight trajectory, dietary intake, treatment adverse effects and simple functional measures such as grip strength, walking speed or the ability to rise from a chair. People at greater risk of muscle loss include older adults, patients with frailty, those who are sedentary and anyone starting treatment with relatively low muscle mass.

Persistent vomiting, dehydration, inability to eat adequately or a noticeable decline in strength should prompt medical assessment. Dose escalation may need to be delayed or reconsidered, but patients should not change or stop a prescribed GLP-1 medicine without consulting the prescriber. The objective is not simply the lowest possible scale weight; treatment should improve metabolic health while preserving nutrition, mobility and quality of life.